New molecular entity
Development and Regulatory status
Nov 17: Development appears to be discontinued in this indication according to the Euthymics Bioscience website .
Triple reuptake inhibitor - serotonin, norepinephrine and dopamine in a ratio of 1: 2: 8
EB-1010 is intended for patients with major depressive disorder (MDD) who do not respond adequately to a single course of SSRI or SNRI. About 66% of patients do not experience remission after initial treatment with SSRIs .